NCT07291284

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis Inadequately Controlled by Standard-of-care

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 546 (actual)
• Sponsor: Longbio Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
BIOLOGICAL	LP-003	Participants were administered LP-003 via subcutaneous injection every 4 weeks.
BIOLOGICAL	Placebo	Participants were administered Placebo via subcutaneous injection every 4 weeks

Timeline

• Start date: 2024-08-01
• Primary completion: 2026-03-31
• Completion: 2026-12-31
• First posted: 2025-12-18
• Last updated: 2025-12-26

Locations

1 site across 1 country: China